Kymera Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Conferences Trial results

16 May 2024

EHA 2024 preview – Novartis doubles up

The conference’s abstract drop features ASC4First in its plenary session.

Subscribe to Kymera Therapeutics